Evidence of differential cisplatin-DNA adduct formation, removal and tolerance of DNA damage in three human lung carcinoma cell lines.
about
Role of copper transporters in platinum resistanceTumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancerCopper transporter CTR1 expression and tissue platinum concentration in non-small cell lung cancer.Genetic variation in DNA-repair pathways and response to radiochemotherapy in esophageal adenocarcinoma: a retrospective cohort study of the Eastern Cooperative Oncology GroupNo evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small cell lung cancer: a meta-analysis.ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis.XRCC3 Thr241Met polymorphism and clinical outcomes of NSCLC patients receiving platinum-based chemotherapy: a systematic review and meta-analysisExosomes: decreased sensitivity of lung cancer A549 cells to cisplatinOrmaplatin resistance is associated with decreased accumulation of its platinum (II) analogue, dichloro(D,L-trans)1,2-diaminocyclohexaneplatinum (II).Tissue platinum concentration and tumor response in non-small-cell lung cancerXRCC1 Arg399Gln and clinical outcome of platinum-based treatment for advanced non-small cell lung cancer: a meta-analysis in 17 studiesKRAS mutational status affects oxaliplatin-based chemotherapy independently from basal mRNA ERCC-1 expression in metastatic colorectal cancer patients.DNA repair capacity in peripheral lymphocytes predicts survival of patients with non-small-cell lung cancer treated with first-line platinum-based chemotherapy.ERCC1 expression affects outcome in metastatic pancreatic carcinoma treated with FOLFIRINOX: A single institution analysis.Genetic variants in ERCC1 and XPC predict survival outcome of non-small cell lung cancer patients treated with platinum-based therapy.
P2860
Q26767028-D1CF8AFB-401F-4B9C-84EA-5E448844FDA3Q28396304-0581860F-88A6-475B-8BB1-C3EEF45FF2DAQ33875938-5F5CB725-BD8C-4F84-A0E1-5A3085E9403AQ33903445-9B1CBB28-4FFD-4F31-BFCD-CF6A3840CB89Q34630819-B1924189-5607-4DEC-AA05-95304C9ABB76Q34694410-D6BCB023-6C7A-4DA7-8A5B-D18BC461AC95Q34934491-7E3975D2-B30F-4F3F-9B15-62C4D168D780Q35107566-42E7A194-6EE5-40BF-870E-B15592BB0010Q36135855-CA786C48-FB5F-4A91-8570-B35FDB5FF565Q36222930-821ED642-203C-47A7-9D5D-B8605BE7D3CFQ36386267-9C25B01E-A506-415B-8878-0BC77D6B29EBQ36557853-B19840AE-2057-442F-9819-1BEA640B86FDQ36910455-11AD8796-DEC4-4DED-B4B7-07BF5301FA93Q37376487-C34FFE8B-0B50-4AF9-B888-5D90DCA65727Q41636798-D1BA8BDF-5CF9-453C-9738-6D6FB82A0232
P2860
Evidence of differential cisplatin-DNA adduct formation, removal and tolerance of DNA damage in three human lung carcinoma cell lines.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
1993年论文
@zh
1993年论文
@zh-cn
name
Evidence of differential cispl ...... man lung carcinoma cell lines.
@en
type
label
Evidence of differential cispl ...... man lung carcinoma cell lines.
@en
prefLabel
Evidence of differential cispl ...... man lung carcinoma cell lines.
@en
P2093
P1433
P1476
Evidence of differential cispl ...... man lung carcinoma cell lines.
@en
P2093
Fichtinger-Schepman AM
Shellard SA
P304
P577
1993-08-01T00:00:00Z